PDF(Pubmed)
Abstract：
Several landmark studies found a relationship between elevated serum uric acid (SUA) levels and cardiovascular disease (CVD). In fact, the association between hyperuricemia and hypertension (HTN), coronary artery disease (CAD), and heart failure (HF) is currently well-established. While the mechanism linking hyperuricemia and CVD is not fully known, a systemic inflammatory response by the host is believed to play a role. With the goal of decreasing the morbidity and mortality of CVD in patients with hyperuricemia, the focus has now turned to properly optimizing a medication regimen for this patient population. Recent studies have shown that controlling underlying inflammation can, in fact, lead to better cardiovascular outcomes for populations with acute and chronic coronary disease. In this paper, we will discuss the current state of understanding on the association of hyperuricemia and cardiovascular disease. Furthermore, we will look into the most recent clinical trials showing the effects anti-inflammatory medications have on both decreasing and recovering from cardiovascular events. We will conclude with a discussion on, given the information mentioned above, how to properly optimize a medication regimen in patients with elevated SUA levels with a focus on decreasing the morbidity and mortality associated with CVD.
摘要：
一些具有里程碑意义的研究发现血清尿酸（SUA）水平升高与心血管疾病（CVD）之间存在关系。事实上,高尿酸血症和高血压（HTN）之间的关系，冠状动脉疾病（CAD），和心力衰竭（HF）是目前公认的。虽然联系高尿酸血症和CVD的机制尚不完全清楚，宿主的全身性炎症反应被认为起作用。为了降低高尿酸血症患者CVD的发病率和死亡率，现在，重点已经转向适当优化该患者人群的药物治疗方案。最近的研究表明，控制潜在的炎症可以，事实上,为急性和慢性冠心病患者带来更好的心血管结局。在本文中,我们将讨论对高尿酸血症和心血管疾病的关系的理解现状。此外，我们将研究最近的临床试验,这些临床试验显示抗炎药对减少和恢复心血管事件的作用.最后我们将讨论，鉴于上述信息，如何正确优化SUA水平升高患者的用药方案，重点是降低与CVD相关的发病率和死亡率。
